Free Trial

Minerva Neurosciences (NERV) Stock Price, News & Analysis

0.00 (0.00%)
(As of 02:13 PM ET)
Today's Range
50-Day Range
52-Week Range
16,846 shs
Average Volume
76,170 shs
Market Capitalization
$23.70 million
P/E Ratio
Dividend Yield
Price Target

Minerva Neurosciences MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
106.5% Upside
$7.00 Price Target
Short Interest
0.27% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.94mentions of Minerva Neurosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.89) to ($3.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.80 out of 5 stars

Medical Sector

232nd out of 912 stocks

Pharmaceutical Preparations Industry

97th out of 434 stocks

NERV stock logo

About Minerva Neurosciences Stock (NASDAQ:NERV)

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

NERV Stock Price History

NERV Stock News Headlines

This is HOW many elite traders think
Want a preview of how elite traders think?! For a limited time, you can claim AI SMS alerts from TradeAlgo for FREE.
This is HOW many elite traders think
Want a preview of how elite traders think?! For a limited time, you can claim AI SMS alerts from TradeAlgo for FREE.
See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($4.07) per share


Free Float
Market Cap
$23.70 million
Not Optionable

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 63)
    Executive Chairman & CEO
    Comp: $1.27M
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 63)
    M.B.A., President
    Comp: $913.3k
  • Mr. Frederick W. Ahlholm CPA (Age 58)
    Senior VP, CFO & Secretary
    Comp: $726.02k
  • Mr. Joseph Reilly (Age 49)
    Senior VP & COO
    Comp: $461k
  • Mr. William B. Boni (Age 72)
    Vice President of Investor Relations & Corporate Communications
  • Prof. Michael Davidson M.D. (Age 74)
    Chief Medical Officer
    Comp: $657.47k

NERV Stock Analysis - Frequently Asked Questions

How have NERV shares performed this year?

Minerva Neurosciences' stock was trading at $6.15 at the start of the year. Since then, NERV shares have decreased by 44.9% and is now trading at $3.39.
View the best growth stocks for 2024 here

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) announced its quarterly earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.07.

When did Minerva Neurosciences' stock split?

Minerva Neurosciences's stock reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

This page (NASDAQ:NERV) was last updated on 7/15/2024 by Staff

From Our Partners